PRNewsWire
25 Dec 2025, 17:59 UTC · 37w ago
Verdict
Headline leans bearish. We score SES −1.00 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish
The FDA issued a Complete Response Letter (CRL) rejecting Alvotech's Biologics License Application (BLA) for AVT05 due to deficiencies at its Reykjavik manufacturing facility.
More negative than 98% of claims this week
The Rosen Law Firm has launched an investigation into potential securities claims against Alvotech for allegedly issuing materially misleading business information.
Continue reading
5 related stories
More negative than 96% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 81% of claims this week
Alvotech's stock price fell approximately 34% on November 3, 2025, following the FDA's CRL announcement.
More negative than 67% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company is mentioned in the context of an investigation for investor losses.
More negative than 96% of ticker scores this week
The company received an FDA complete response letter and is facing a securities class action investigation following a significant stock price drop.
More negative than 96% of ticker scores this week
The company is the subject of a securities fraud lawsuit.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
4h ago
−72.4%
Price agrees with the score
$0.5621 vs $2.04 close before publication (Dec 24) · not market-adjusted
SES chart →
